Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 29 of 318 for:    FLUTICASONE AND SALMETEROL

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium (ARGON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03158311
Recruitment Status : Completed
First Posted : May 18, 2017
Last Update Posted : September 20, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this trial is to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 is non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium in uncontrolled asthmatics.

Condition or disease Intervention/treatment Phase
Asthma Drug: QVM149 Drug: Salmeterol/fluticasone plus tiotropium Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1436 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: The free triple combination of salmeterol/fluticasone + tiotropium is open label for which investigators and patients will have full knowledge the patient has been assigned free triple combination comparator treatment. Within the two QVM149 treatment arms patients, investigator staff, and persons performing the assessments, will remain blind to the identity of the actual QVM149 treatment dose but will have full knowledge that the patient has been assigned QVM149 as study treatment. The data analysts and sponsor team will be blinded to Case Report Forms that reveal the treatment arm. Randomization data and treatment codes are kept strictly confidential until the time of unblinding, and will not be accessible by anyone else involved in the study.
Primary Purpose: Treatment
Official Title: A Multicenter, Partially-blinded, Randomized, 24-week, Parallel-group, Non-inferiority, Open-label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma
Actual Study Start Date : February 5, 2018
Actual Primary Completion Date : July 12, 2019
Actual Study Completion Date : July 19, 2019


Arm Intervention/treatment
Experimental: QVM149 arm 1
QVM149 150/50/80 μg o.d. delivered via Concept1
Drug: QVM149
Indacaterol acetate / Glycopyrronium bromide / Mometasone furoate

Experimental: QVM149 arm 2
QVM149 150/50/160 μg o.d. delivered via Concept1
Drug: QVM149
Indacaterol acetate / Glycopyrronium bromide / Mometasone furoate

Active Comparator: Salmeterol/fluticasone plus tiotropium arm
Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
Drug: Salmeterol/fluticasone plus tiotropium
free triple arm of Salmeterol/fluticasone plus tiotropium




Primary Outcome Measures :
  1. Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) total score [ Time Frame: 24 weeks ]
    The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma.


Secondary Outcome Measures :
  1. Change from baseline in Trough FEV1 [ Time Frame: 8 weeks, 16 weeks, 24 weeks ]
    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.

  2. Change from baseline in Asthma Control Questionnaire (ACQ-7) total score [ Time Frame: 16 weeks, 24 weeks ]
    ACQ is the Asthma Control Questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and the rescue medication use entered by the patient) validated to evaluate different levels of asthma control

  3. Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) total score [ Time Frame: 16 weeks ]
    The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma.

  4. Percentage of patients achieving the minimal important difference (MCID) change from baseline ACQ-7 ≥ 0.5 decrease [ Time Frame: 16 weeks, 24 weeks ]
    Responder rate; MCID for ACQ-7 is 0.5 decrease.

  5. Percentage of patients achieving the minimal important difference (MCID) change from baseline AQLQ ≥ 0.5 increase [ Time Frame: 16 weeks, 24 weeks ]
    Responder rate; MCID for AQLQ is 0.5 increase.

  6. Change from baseline in Forced Vital Capacity (FVC) [ Time Frame: 8 weeks, 16 weeks, 24 weeks ]
    FVC is the total amount of air exhaled during the FEV test.

  7. Change from baseline in Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity (FEF25-75) [ Time Frame: 8 weeks, 16 weeks, 24 weeks ]
    Forced expiratory flow during the mid (25 - 75%) portion of the FVC.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Patients with a diagnosis of asthma for a period of at least 6 months prior to Visit 1 with current asthma severity ≥ step 4 (GINA 2017).

Patients who have used ICS/LABA combinations for asthma for at least 3 months and at stable medium or high dose of ICS/LABA for at least 1 month prior to Visit 1.

  • Patients must be symptomatic at screening despite treatment with medium or high stable doses of ICS/LABA as defined by ACQ-7 score ≥ 1.5 at visits 101 and 201 (randomization visit).
  • Patients with history of at least one severe asthma exacerbation (see section 6.4.5) which required medical care from a physician, ER visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1 and required systemic corticosteroid treatment for at least 3 days including physician guided self-management treatment with oral corticosteroids as part of written asthma action plan.
  • Pre-bronchodilator FEV1 of < 85 % of the predicted normal value for the patient after withholding bronchodilators prior to spirometry at both Visit 101 and Visit 201.
  • Patients who demonstrate an increase in FEV1 of ≥ 12% and 200 mL.

Exclusion Criteria:

  • Patients who have a smoking history of greater than 20 pack years.
  • Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).
  • Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening).
  • Patients treated with a LAMA for asthma within 3 months prior to Visit 1.
  • Patients who have had a respiratory tract infection or clinical significant asthma worsening as defined by Investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit 201.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03158311


  Show 180 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03158311     History of Changes
Other Study ID Numbers: CQVM149B2306
First Posted: May 18, 2017    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
QVM149
asthma
adult
Additional relevant MeSH terms:
Layout table for MeSH terms
Fluticasone
Salmeterol Xinafoate
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Tiotropium Bromide
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents